U.S. markets closed
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • Dow 30

    31,535.51
    +603.14 (+1.95%)
     
  • Nasdaq

    13,588.83
    +396.48 (+3.01%)
     
  • Russell 2000

    2,275.32
    +74.27 (+3.37%)
     
  • Crude Oil

    60.27
    -0.37 (-0.61%)
     
  • Gold

    1,721.70
    -1.30 (-0.08%)
     
  • Silver

    26.58
    -0.09 (-0.35%)
     
  • EUR/USD

    1.2053
    -0.0035 (-0.29%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • GBP/USD

    1.3925
    +0.0003 (+0.02%)
     
  • USD/JPY

    106.8010
    +0.2990 (+0.28%)
     
  • BTC-USD

    49,590.95
    +4,553.65 (+10.11%)
     
  • CMC Crypto 200

    982.63
    +54.40 (+5.86%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

  • Oops!
    Something went wrong.
    Please try again later.
GenMark Diagnostics, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 6957136 approximately five minutes prior to the start time.

ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com